I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450

Alexandria, VA 22313 on October 19, 2000

Frank C. Eisenschenk, Ph.D., Patent Attorney

AMENDMENT UNDER 37 CFR §1.825(a) THROUGH (c) Patent Application Docket No. SER-111 Serial No. 10/582,027

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

Maria Dorly Del Curto

Serial No.

10/582,027

Filed

June 8, 2006

Conf. No.

1354

For

Stabilized Interferon Liquid Formulations

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## AMENDMENT UNDER 37 CFR §1.825(a) THROUGH (c)

Sir:

In response to the Notification to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures received in the aboveidentified patent application, please amend the subject application as follows, in order to comply with the requirements of 37 CFR §§1.821-1.825: